Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
April 28, 2022
- Products Filed for Conditional OK Can Be Switched to Emergency Approval: MHLW Official
April 27, 2022
- Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- MHLW to Further Bankroll Shionogi’s COVID-19 Pill, Kowa’s Ivermectin
April 25, 2022
- Japan to Raise Pharmacy Stock Levels for Lagevrio, Paxlovid
April 25, 2022
- Upper House Starts Deliberations on PMD Law Amendment Bill
April 25, 2022
- Single-Year Comparison of PMP and Deferred Price Cuts Not Appropriate: Health Minister
April 22, 2022
- Comirnaty, Spikevax for PAFSC Review on April 25; HSC to Discuss 4th Shot on April 27
April 22, 2022
- LDP Adopts Proposal on 4th COVID-19 Vaccination, Urges Govt to Ponder Cost-Effectiveness
April 20, 2022
- Japan’s Lower House OKs PMD Law Amendment Bill
April 20, 2022
- SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
- Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
- Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
- Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
- Secure New mRNA Jabs, 4th Shots for Older Adults and People with Medical Conditions: LDP
April 18, 2022
- Japan PM Sees INES’ Macroeconomic Indexing Pitch as One Suggestion
April 18, 2022
- MHLW Panel to Review Rosacea Indication for Rozex on April 28
April 15, 2022
- No Major Safety Concerns for COVID-19 Jabs for Adults and Children: MHLW Panels
April 15, 2022
- Sort Out Challenges, Pricing Issues to Boost Innovation, Economic Security: CEFP
April 14, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…